Stryker (NYSE:SYK) PT Raised to $375.00 at Stifel Nicolaus

Stryker (NYSE:SYK) had its price objective increased by investment analysts at Stifel Nicolaus from $350.00 to $375.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical technology company’s stock. Stifel Nicolaus’ price target points to a potential upside of 11.94% from the company’s current price.

Several other equities analysts have also weighed in on SYK. Citigroup raised their price objective on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Wells Fargo & Company raised their price objective on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. Truist Financial raised their price objective on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research report on Wednesday, January 31st. Roth Mkm raised their price objective on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $347.62.

Stryker Stock Down 0.4 %

Stryker stock opened at $335.00 on Wednesday. The stock has a market cap of $127.46 billion, a price-to-earnings ratio of 40.77, a PEG ratio of 2.73 and a beta of 0.89. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The company’s 50-day moving average price is $348.44 and its two-hundred day moving average price is $316.70. Stryker has a 52 week low of $249.98 and a 52 week high of $361.41.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. The firm had revenue of $5.24 billion for the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. Stryker’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the company earned $2.14 EPS. On average, analysts expect that Stryker will post 11.86 EPS for the current fiscal year.

Insider Activity at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 212,109 shares of company stock valued at $72,845,768. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Stryker

Hedge funds and other institutional investors have recently modified their holdings of the stock. Keybank National Association OH grew its stake in shares of Stryker by 3.5% in the third quarter. Keybank National Association OH now owns 27,823 shares of the medical technology company’s stock worth $7,603,000 after acquiring an additional 952 shares during the last quarter. Carnegie Capital Asset Management LLC grew its stake in shares of Stryker by 0.5% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock worth $28,820,000 after acquiring an additional 497 shares during the last quarter. CoreCap Advisors LLC grew its stake in shares of Stryker by 3.9% in the fourth quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock worth $1,506,000 after acquiring an additional 191 shares during the last quarter. Consolidated Planning Corp acquired a new stake in shares of Stryker in the fourth quarter worth $205,000. Finally, Meritage Portfolio Management acquired a new stake in shares of Stryker in the fourth quarter worth $569,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.